Literature DB >> 11258554

Hyperhomocysteinemia in Greek patients with inflammatory bowel disease.

I E Koutroubakis1, E Dilaveraki, I G Vlachonikolis, E Vardas, G Vrentzos, E Ganotakis, I A Mouzas, A Gravanis, D Emmanouel, E A Kouroumalis.   

Abstract

In recent years hyperhomocysteinemia has been established as a new risk factor for arterial and venous thrombosis. Since patients with inflammatory bowel disease (IBD) frequently suffer from thromboembolic events, we studied the prevalence and clinical significance of hyperhomocysteinemia in Greek patients with ulcerative colitis (UC) and Crohn's disease (CD). In 108 consecutive fasting IBD patients (53 UC and 55 CD) and 74 healthy controls (HC), a standard record of various clinical thrombotic risk factors was completed by interview, and fasting serum concentrations of total homocysteine (tHcy), folate, cobalamin, creatinine, cholesterol, HDL, LDL, and triglycerides were measured. The concentration (mean +/- SD) of serum tHcy was significantly higher in UC (15.9 +/- 10.3 micromol/liter) and CD patients (13.6 +/- 6.5) than in controls (9.6 +/- 3.4, P < 0.05). Both UC and CD patients had lower levels of folate than HC (P < 0.05). Covariance analysis of age, gender, and all clinical variables indicated that the differences in homocysteine levels between IBD patients and HC remain significant even after adjustment for these covariates. In conclusion, mild hyperhomocysteinemia is common in Greek IBD patients and may account for the increased thrombotic risk of these patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11258554     DOI: 10.1023/a:1005583606647

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  29 in total

Review 1.  Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence.

Authors:  J W Eikelboom; E Lonn; J Genest; G Hankey; S Yusuf
Journal:  Ann Intern Med       Date:  1999-09-07       Impact factor: 25.391

2.  Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease.

Authors:  I E Koutroubakis; E Petinaki; E Anagnostopoulou; H Kritikos; I A Mouzas; E A Kouroumalis; O N Manousos
Journal:  Dig Dis Sci       Date:  1998-11       Impact factor: 3.199

3.  High prevalence of hyperchomocysteinemia in patients with inflammatory bowel disease: a pathogenic link with thromboembolic complications?

Authors:  M Cattaneo; M Vecchi; M L Zighetti; S Saibeni; I Martinelli; P Omodei; P M Mannucci; R de Franchis
Journal:  Thromb Haemost       Date:  1998-10       Impact factor: 5.249

4.  Inherited disorders of coagulation appear to protect against inflammatory bowel disease.

Authors:  N P Thompson; A J Wakefield; R E Pounder
Journal:  Gastroenterology       Date:  1995-04       Impact factor: 22.682

5.  Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease.

Authors:  J G Ray
Journal:  Arch Intern Med       Date:  1998-10-26

6.  Prothrombin fragment 1 + 2 and thrombin-antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel diseases.

Authors:  P Chamouard; L Grunebaum; M L Wiesel; P L Frey; C Wittersheim; R Sapin; R Baumann; J P Cazenave
Journal:  Eur J Gastroenterol Hepatol       Date:  1995-12       Impact factor: 2.566

7.  Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease.

Authors:  I Fermo; S Vigano' D'Angelo; R Paroni; G Mazzola; G Calori; A D'Angelo
Journal:  Ann Intern Med       Date:  1995-11-15       Impact factor: 25.391

8.  Paradoxical response to heparin in 10 patients with ulcerative colitis.

Authors:  P R Gaffney; C T Doyle; A Gaffney; J Hogan; D P Hayes; P Annis
Journal:  Am J Gastroenterol       Date:  1995-02       Impact factor: 10.864

9.  Hyperhomocysteinemia as a risk factor for deep-vein thrombosis.

Authors:  M den Heijer; T Koster; H J Blom; G M Bos; E Briet; P H Reitsma; J P Vandenbroucke; F R Rosendaal
Journal:  N Engl J Med       Date:  1996-03-21       Impact factor: 91.245

10.  The factor V Leiden mutation increases the risk of venous thrombosis in patients with inflammatory bowel disease.

Authors:  H A Liebman; N Kashani; D Sutherland; W McGehee; A L Kam
Journal:  Gastroenterology       Date:  1998-10       Impact factor: 22.682

View more
  12 in total

1.  Increased levels of homocysteine in patients with ulcerative colitis.

Authors:  Sabiye Akbulut; Emin Altiparmak; Firdevs Topal; Ersan Ozaslan; Metin Kucukazman; Ozlem Yonem
Journal:  World J Gastroenterol       Date:  2010-05-21       Impact factor: 5.742

2.  Hyperhomocysteinemia in ulcerative colitis is related to folate levels.

Authors:  Petros Zezos; Georgia Papaioannou; Nikolaos Nikolaidis; Themistoclis Vasiliadis; Olga Giouleme; Nikolaos Evgenidis
Journal:  World J Gastroenterol       Date:  2005-10-14       Impact factor: 5.742

3.  Hyperhomocysteinemia in patients with Crohn's disease.

Authors:  G Casella; E Antonelli; C Di Bella; E Di Marco; M Piatti; V Villanacci; S Bologna; V Baldini; G Bassotti
Journal:  Tech Coloproctol       Date:  2013-03-08       Impact factor: 3.781

4.  Effects of hyperhomocysteinemia on non-adrenergic non-cholinergic relaxation in isolated rat duodenum.

Authors:  Edibe Karasu; Gülay Sadan; Arda Tasatargil
Journal:  Dig Dis Sci       Date:  2008-06-06       Impact factor: 3.199

5.  Hospitalizations for Acute Myocardial Infarction Are Decreased Among Patients with Inflammatory Bowel Disease Using a Nationwide Inpatient Database.

Authors:  Edward L Barnes; Renee M Beery; Allison R Schulman; Ellen P McCarthy; Joshua R Korzenik; Rachel W Winter
Journal:  Inflamm Bowel Dis       Date:  2016-09       Impact factor: 5.325

6.  Increased folate intake with no changes in serum homocysteine and decreased levels of C-reactive protein in patients with inflammatory bowel diseases.

Authors:  P G Chiarello; F R O Penaforte; C C Japur; C D A S Souza; H Vannucchi; L E A Troncon
Journal:  Dig Dis Sci       Date:  2008-07-17       Impact factor: 3.199

7.  Homocysteine, cysteine, and glutathione in human colonic mucosa: elevated levels of homocysteine in patients with inflammatory bowel disease.

Authors:  I Morgenstern; M T M Raijmakers; W H M Peters; H Hoensch; W Kirch
Journal:  Dig Dis Sci       Date:  2003-10       Impact factor: 3.199

8.  Biomarkers of one-carbon metabolism are associated with biomarkers of inflammation in women.

Authors:  Clare Abbenhardt; Joshua W Miller; Xiaoling Song; Elissa C Brown; Ting-Yuan David Cheng; Mark H Wener; Yingye Zheng; Adetunji T Toriola; Marian L Neuhouser; Shirley A A Beresford; Karen W Makar; Lynn B Bailey; David R Maneval; Ralph Green; Joann E Manson; Linda Van Horn; Cornelia M Ulrich
Journal:  J Nutr       Date:  2014-03-19       Impact factor: 4.798

Review 9.  An overview of lipid abnormalities in patients with inflammatory bowel disease.

Authors:  Aris P Agouridis; Moses Elisaf; Haralampos J Milionis
Journal:  Ann Gastroenterol       Date:  2011

10.  Low bone mineral density in Greek patients with inflammatory bowel disease: prevalence and risk factors.

Authors:  Ioannis E Koutroubakis; Christos Zavos; John Damilakis; Georgios Z Papadakis; John Neratzoulakis; Nikolaos Karkavitsas; Elias A Kouroumalis
Journal:  Ann Gastroenterol       Date:  2011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.